Rydapt

註冊用途：
   與標準daunorubicin和cytarabine引導化療和高劑量cytarabine鞏固化療併用，用於使用單一維持治療有完全反應，新確診FLT3突變陽性的急性骨髓性白血病(AML)成年患者
   In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by single agent maintenance therapy for adult patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML)
   用作單一治療，治療侵犯性全身性肥大細胞增生症(ASM), 伴有血液腫瘤的系统性肥大细胞增生症 (SM-AHN)，或肥大細胞白血病(MCL)的成年患者
   As monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL)
有關服務：
有關文章：
有關視頻：